Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies

INTRODUCTION: Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first‐line vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Wiele, Andrew J., Bathala, Tharakeswara K., Hahn, Andrew W., Xiao, Lianchun, Duran, Munevver, Ross, Jeremy A., Jonasch, Eric, Shah, Amishi Y., Campbell, Matthew T., Msaouel, Pavlos, Tannir, Nizar M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2021
Schlagworte:
Genitourinary Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176993/
https://ncbi.nlm.nih.gov/pubmed/33792094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13770
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge